Swartz S L, Dluhy R G
Drugs. 1978 Sep;16(3):238-55. doi: 10.2165/00003495-197816030-00006.
The widespread use of corticosteroids in clinical practice emphasises the need for a thorough understanding of their metabolic effects. In general, the actions of corticosteroids on carbohydrate, protein, and lipid metabolism result in increased hepatic capacity for gluconeogenesis and enhanced catabolic actions upon muscle, skin, lymphoid, adipose and connective tissues. Because of the morbidity associated with steroid therapy, the clinician must carefully consider in each case the gains that can reasonably be expected from corticosteroid therapy versus the inevitable undesirable side effects of prolonged therapy. Thus, it is important to remember that the enhanced anti-inflammatory activity of the various synthetic analogues of cortisol is not dissociated from the expected catabolic actions of glucocorticoid hormones. Replacement therapy with physiological doses of cortisol in primary or secondary adrenal insufficiency is intended to simulate the normal daily secretion of cortisol. Short term, high dose suppressive glucocorticoid therapy is indicated in the treatment of medical emergencies such as necrotising vasculitis, status asthmaticus and anaphylactic shock. With improvement of the underlying disorder, the steroid dosage can be rapidly tapered and then discontinued over a 2 to 3 day period. Long term, high dose suppressive therapy is often commonly used to treat certain diseases (see sections 4.7.2 and 4.7.3). In this setting, suppression of the hypothalamic-pituitary-adrenal axis may persist for as long as 9 to 12 months following steroid withdrawal if steroid doses are administered in the supraphysiological range for longer than 2 weeks. In general, higher doses, longer duration of usage, and frequent daily administration are all correlated with the severity of pituitary ACTH suppression. When steroid therapy is to be withdrawn, gradual tapering of the dosage is necessary; the steroid dosage should also be given as a single morning dose if possible. Rapid or total withdrawal of the steroid therapy may be associated with exacerbation of the underlying disease or with a steroid withdrawal syndrome. An additional important point to remember in any withdrawal programme is that the steroid dosage should be appropriately increased for an exacerbation of the underlying disease or for intercurrent major stress. Alternate day therapy is recommended as a steroid maintenance programme for patients requiring high dose glucocorticoid therapy over a prolonged period of time. Thus, it is usually employed to maintain a therapeutic benefit which had previously been extablished by daily steroid treatment. Complications resulting from corticosteroid therapy include: (1) proximal muscle weakness; (2) osteopenia; (3) unmasking of latent diabetes mellitus; (4) sodium retention and/or elevation of mean arterial blood pressure; (5) adverse psychiatric reactions; (6) development of glaucoma; and (7) reactivation of latent infections (such as tuberculosis).
皮质类固醇在临床实践中的广泛应用凸显了全面了解其代谢作用的必要性。一般来说,皮质类固醇对碳水化合物、蛋白质和脂质代谢的作用会导致肝脏糖异生能力增强,并增强对肌肉、皮肤、淋巴、脂肪和结缔组织的分解代谢作用。由于类固醇治疗存在相关发病率,临床医生在每种情况下都必须仔细权衡皮质类固醇治疗可能带来的合理益处与长期治疗不可避免的不良副作用。因此,重要的是要记住,各种皮质醇合成类似物增强的抗炎活性与糖皮质激素预期的分解代谢作用并非毫无关联。在原发性或继发性肾上腺功能不全中,用生理剂量的皮质醇进行替代治疗旨在模拟皮质醇的正常每日分泌。短期、高剂量的糖皮质激素抑制疗法适用于治疗诸如坏死性血管炎、哮喘持续状态和过敏性休克等医疗急症。随着基础疾病的改善,类固醇剂量可迅速减量,然后在2至3天内停用。长期、高剂量的抑制疗法通常用于治疗某些疾病(见4.7.2和4.7.3节)。在这种情况下,如果类固醇剂量在超生理范围内使用超过2周,那么在停用类固醇后,下丘脑 - 垂体 - 肾上腺轴的抑制可能会持续长达9至12个月。一般来说,更高的剂量、更长的使用时间和每日频繁给药都与垂体促肾上腺皮质激素(ACTH)抑制的严重程度相关。当要停用类固醇治疗时,有必要逐渐减量;如果可能的话,类固醇剂量也应在早晨单次给药。快速或完全停用类固醇治疗可能会导致基础疾病加重或出现类固醇戒断综合征。在任何停药方案中,另一个需要记住的重要点是,对于基础疾病加重或并发重大应激情况,应适当增加类固醇剂量。隔日疗法被推荐作为需要长期高剂量糖皮质激素治疗的患者的类固醇维持方案。因此,它通常用于维持先前通过每日类固醇治疗所确立的治疗效果。皮质类固醇治疗引起的并发症包括:(l)近端肌无力;(2)骨质减少;(3)隐匿性糖尿病被暴露;(4)钠潴留和/或平均动脉血压升高;(5)不良精神反应;(6)青光眼的发生;以及(7)潜伏感染(如结核病)的复发。